Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068928 | 0.86 | LMNA (0.37) | LMNAALDH1A1ALOX15TSHRNR1I2 | |
| SCHEMBL29350081 | 0.86 | LMNA (0.37) | LMNAALDH1A1ALOX15TSHRNR1I2 | |
| SCHEMBL11775855 | 0.84 | LMNA (0.52) | LMNAALDH1A1ALOX15TSHRNR1I2 | |
| SCHEMBL30696400 | 0.84 | LMNA (0.52) | LMNAALDH1A1ALOX15TSHRNR1I2 | |
| SCHEMBL14438127 | 0.82 | LMNA (0.34) | LMNAALDH1A1ALOX15TSHR | |
| SCHEMBL31490074 | 0.78 | ALDH1A1 (0.47) | LMNAALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL22119900 | 0.78 | ALDH1A1 (0.47) | LMNAALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL21918463 | 0.77 | NR1I2 (0.40) | LMNANR1I2AHR | |
| SCHEMBL17006829 | 0.75 | LMNA (0.42) | LMNANR1I2AHRIDO1 | |
| SCHEMBL1586662 | 0.73 | ALDH1A1 (0.47) | LMNAALDH1A1ALOX15TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106910-A1 | DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR | FLARE THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025043148-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | DRAIG THERAPEUTICS LTD (GB) | 2024-12-26 | — | — | US | disclosed |
| US-20240254138-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-01 | — | — | US | disclosed |
| EP-4334301-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | University College Cardiff Consultants Limited (GB) | 2024-03-13 | — | — | EP | disclosed |
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
| EP-4305040-A1 | TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| CN-117279908-A | Heteroaryl compounds for the treatment of cognitive disorders | 加的夫大学学院咨询有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116940577-A | Tricyclic pyridines as cyclin dependent kinase 7 (CDK 7) inhibitors | 詹森药业有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4211118-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | Cerevance, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20060058326-A1 | Pyrimidines, methods for the production thereof, and use thereof | BASF AKTIENGESLLSCHAFT (DE) | 2006-03-16 | — | — | US | disclosed |
| EP-1592695-A1 | PYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069846-A1 | PYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | WO | disclosed |
| US-4871387-A | Pyri(mi)dyl-oxy-and -thio-benzoic acid derivatives useful as herbicides and plant growth regulants | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-03 | — | — | US | disclosed |
| US-4797146-A | INSECTICIDES, FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1989-01-10 | — | — | US | disclosed |
| EP-0226885-A1 | Pyrimidylmercapto-acylanilides | BAYER AG (DE) | 1987-07-01 | — | — | EP | disclosed |
| EP-0226837-A2 | Pyri(mi)dyloxy and -thiobenzoic acid derivatives | BAYER AG (DE) | 1987-07-01 | — | — | EP | disclosed |
| EP-0033195-B1 | PYRIMIDINE-2-SULPHIDES AND THEIR S-OXIDES FOR USE IN MEDICINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESSES FOR THEIR PREPARATION AND SUCH COMPOUNDS WHEN NOVEL PER SE | NYEGAARD & CO. A/S (NO) | 1985-12-04 | — | — | EP | disclosed |
| US-4423047-A | INHIBITING ABNORMAL CELL PROLIFERATION | NYEGAARD & CO. A/S (NO) | 1983-12-27 | — | — | US | disclosed |
| EP-0033195-A1 | Pyrimidine-2-sulphides and their S-oxides for use in medicine, pharmaceutical compositions containing them, processes for their preparation and such compounds when novel per se | NYEGAARD & CO. A/S (NO) | 1981-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CHRNA6, CHRM2, CHRNA1 | LMNA 2173/4885ALDH1A1 318/4885ALOX15 3266/4885 |
| US-20240254138-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | CDK7, CDK2, CCNK | LMNA 1633/4885ALDH1A1 2910/4885ALOX15 3340/4885 |
| US-20060058326-A1 | Pyrimidines, methods for the production thereof, and use thereof | CBR3, CBR1, C5 | LMNA 236/4885ALDH1A1 2010/4885ALOX15 152/4885 |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | GABRA5, GABRB3, GABRA3 | LMNA 3802/4885ALDH1A1 1189/4885ALOX15 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.